Thursday, 7 August 2014

Perennial Allergic Rhinitis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Perennial Allergic Rhinitis Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Rhinitis is an acute disease of the nasal system. Rhinitis is the irritation and inflammation of the internal lining and mucous membrane of the nose. The rhinitis is one of the short term and environment related disorders, which is identified by common symptoms, such as, runny nose, stuffy nose and post-nasal drip.
Among various types of rhinitis, allergic rhinitis is the most common disease. Allergic rhinitis, as the name indicates, occurs due to various allergy propelling factors, such as, pollen grains, dust, mist, fog, and other airborne allergens. When these allergens are inhaled by immune-sensitive person, it triggers the production of IgE (immunoglobulin E antibody). IgE triggers the histamine secretion, which leads to irritation and inflammation of mucous membrane. Perennial allergic rhinitis is the most common and frequently occurring type of allergic rhinitis.
The major symptoms of the disease include itching, sneezing, rhinorrhea, nasal obstruction and congestion. Sometimes, rhinitis may occur due to chronic diseases, such as, asthma, eczema and depression. The causes of the disease include pollens and airborne allergens of various natural origin, such as, trees, weeds and grasses. The disease is diagnosed by using Radio Allergo Sorbent Testing (RAST) blood test, skin test (patch test), skin prick test, and allergen sensitivity test.
The market of perennial allergic rhinitis is segmented on the basis of drugs classes used for the treatment, such as, steroids, antihistamines, allergen immunotherapy formulations, decongestants, and other complimentary treatments. Steroids class mainly includes intranasal corticosteroids, prednisolone, beclometasone, and triamcinolone acetonide. Whereas, antihistamines class include citrizine, chlorphenamine, promethazine, acrivastine, loratadine and others. Allergen immunotherapy formulations mainly include desensitizing vaccines. Decongestants mainly include phenylephrine hydrochloride and others. Other treatments include cromolyn formulations (sodium cromoglycate as anti-inflammatory agent), leukotriene receptor antagonists and others. Further, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The European region is the most dominating market in the world, owing to large number of perennial allergic rhinitis diagnosed patients. On the other hand, Asia-Pacific and RoW regions are the most promising markets in upcoming period, owing to rising awareness and treatment of disease and rising prevalence of disorder, and growth of medical infrastructure.
The market of perennial allergic rhinitis is expected to show steady growth during the forecast period 2014 – 2020. This growth is driven by various factors, such as extensive R&D practices to develop new and more effective products and formulations, rising number of patients, changes in lifestyle and other environmental conditions. These factors are coupled with rising awareness about the disease and its diagnosis. According to World Allergy Organization (WAO), the prevalence of allergic rhinitis varies from 1.4% to 40% in various countries of the world. European and APAC countries are the most prevalent to disease, due to frequently varying environmental and climatic conditions. According to American College of Asthma, Allergy and Immunology (ACAAI), in 2010, around 16.9 million adults and 6.7 million children were diagnosed with hay fever. This high prevalence of the disease is anticipated to propel the growth of the market during the forecast period 2014 – 2020. Further, due to extensive R&D practices, a number of new formulations for the treatment of perennial allergic rhinitis are under pipeline studies. For instance, formulations like S-555739, desloratadine, GMNL-32 and many others are under pipeline studies and are expected to enter in the market during upcoming 5-10 years.
Hence, this fact is expected to fuel growth of the market. Major restraints include ignorance towards the disease and side effects of the therapy, which may limit the growth of the market to certain extent.
Some of the major players operating in this market include Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Hanmi Pharmaceuticals, Inc. amongst others.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Followed LinkedIn :-https://www.linkedin.com/today/post/article/20140808063513-349336221-perennial-allergic-rhinitis-market
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY — 12207
United States
Tel: +1-518-618-1030
USA — Canada Toll Free 866-552-3453

Browse Market Research Blogs:

Primary Systemic Amyloidosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Primary Systemic Amyloidosis Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs where amyloids get deposited and result in various localized complications. Deposition of amyloids in the heart causes continuous progression towards heart failure by cardiomyopathy, accumulation of amyloids renal system causes renal dysfunction and hepatomegaly can happen because of amyloids infiltration in the liver. Generally diagnosis of this disease is delayed because of no specific symptoms associated with it; however, some symptoms associated with disease include severe fatigue with weakness, feeling of satiety every time, difficulty in swallowing, swelling of tongue. There are several tests used for diagnosis of primary systemic amyloidosis depending on the organ affected, out of which Urinalysis, whole blood count, test for high creatinine level and liver function test are common.
Though primary systemic amyloidosis is very rare disease but it has spread across the world. According to article published by American Society of Nephrology (ASN), it is estimated that around five to twelve people per million per year are affected by primary systemic amyloidosis. At the same time, several numbers of cases of this disease remain undiagnosed. The scenario is similar in all regions of the world. All these facts represent significant demand of the various treatment options for primary systemic amyloidosis globally. The investment in research and development, suitable reimbursement conditions and advancements in diagnosis technologies may drive the growth of the market. On the other hand high cost involved in treatment and limited awareness may hinder the growth of the overall market. Currently there are many research projects under study that are focused on advancement in the treatment of primary systemic amyloidosis. Celgene Corporation in collaboration with Italian institute Fondazione I.R.C.C.S. - Policlinico San Matteo studying the use of of cyclophosphamide, lenalidomide and dexamethasone for previously treated patients with primary systemic amyloidosis, Boston University evaluating the safety and effect of doxycycline in patients with amyloidosis, French Nantes University Hospital studying the effect of lenalidomide in combination with melphalan and dexamethasone in newly-diagnosed patients, National Cancer Institute (NCI) in collaboration with Mayo Clinic using evaluating the use of lenalidomide, cyclophosphamide, and dexamethasone in treating patients with primary systemic amyloidosis.
Primary systemic amyloidosis market can be segmented according to different categories such as regional geography and available treatment options. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region will have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The market can also be segmented according to treatment options such as enzyme inhibitors, immune modulators, diuretics and others. The market can be divided according to symptomatic therapies.
Currently many established players in pharmaceuticals and biotechnology market catering varied range of products in this market. Out of these companies, Prothena Corporation plc, Celgene Corporation and Onclave Therapeutics Limited Llc are leading contributors.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY — 12207
United States
Tel: +1-518-618-1030
USA — Canada Toll Free 866-552-3453

Browse Market Research Blogs:


Wednesday, 6 August 2014

MDD, Anxiety and Panic Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “MDD, Anxiety and Panic Disorder Therapeutics Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Epidemiologic studies have concluded that majority of the individuals experiencing panic attack will also experience a major depression disorder (MDD) and this factor increases the possibility of co-occurrence of panic disorder. These disorders tend in functional disability along with suicidal behavior in the patients and are in association with depression and panic conditions. Anxiety symptoms include obsessive, obtrusive, worried thoughts, irritability, confusion and difficulty concentrating and frustration. Person with anxiety also feel uncomfortable physical sensations, tense some characteristics such as trembling, a racing heartbeat, sweating, difficulty breathing and nausea. The sudden onset of such symptoms is often an indicator of a severe panic attack. Anxiety can also lead to lightheadedness, headaches, digestive problems and insomnia.
According to National Comorbidity Survey Replication, the prevalence for an anxiety disorder was about 18%, and for mood disorder it was 9.5% every year. Lifetime prevalence for any anxiety disorder and MDD were approximately 29% and 16.6%, respectively. Assuming a 50% comorbidity rate, between 5% and 9% of the adult population has comorbid depression-anxiety in a year’s time. The treatment against these comorbid depression and anxiety disorder are cognitive-behavioral therapy (CBT) as an effective psychological treatment but it needs support from therapeutic drugs where anti-depressants are observed to be the first-line of treatment for comorbid depression and anxiety disorders.
But in this disorder the anti-depressants may turn into panic attacks for patients when they have undetected bipolar disorder which should be analyzed by mapping the family history of patient before treatment. According to World Health Organization (WHO), neuropsychiatric disorders accounted for more than 13% of all medical disability worldwide and for more than 27% of all noncommunicable disease in 2005. Depression alone produced 10% to 12% of all disability from noncommunicable disease and approximately 5% of all disability (noncommunicable, communicable, injury). Thus, comorbid anxiety and depression may account for as much as 2% to 4% of all medical disability worldwide. The antidepressants particularly used in this treatment are serotonin-specific reuptake inhibitor (SSRI) such as escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, sertraline and Serotonin-norepinephrine reuptake inhibitors (SNRI) is venlafaxine that are observed to be the first-line pharmacotherapy for depression and anxiety disorders.
The recent updates regarding major depression disorder (MDD), anxiety and panic disorder market is about to go through a vibrant phase with forthcoming patent expiries for leading products such as BMS/Otsuka’s Abilify and Eli Lilly's Cymbalta, and in January 2014 the recent launch of, Lundbeck/Takeda's Brintellix a multimodal antidepressant. The other devices present in the pipeline are Richter/Mitsubishi Tanabe Pharma’s cariprazine, Naurex’s GLYX-13, Forest (Actavis)/Gedeon and Alkermes’s ALKS-5461 along with antidepressant therapies such as Lundbeck/Takeda’s tedatioxetine, e-Therapeutics’ ETS6103 and Euthymics Bioscience’s amitifadine. The overall major depression disorder (MDD), anxiety and panic disorder market is about to observe a significant growth in the market. As the drivers impacting this market are primarily increasing the amount of stress and lack of sleep in adult population that are having various psychological problems.
Some of the key players in the Major Depression Disorder (MDD), anxiety and panic disorder market are Shire Plc, Forest Laboratories, Novartis AG, Astra Zeneca Plc, Eli Lilly and Company, Pfizer, Inc., Janssen Pharmaceuticals, Inc. (JPI), BTG International (BTG), H. Lundbeck A/S, Alexza Pharmaceuticals and others.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY — 12207
United States
Tel: +1-518-618-1030
USA — Canada Toll Free 866-552-3453

Browse Market Research Blogs:

Lymphoblastic Lymphoma Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Lymphoblastic Lymphoma Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Lymphobalstic lymphoma is also known as non-hodgkin lymphoma a type of cancer that primarily affects lymphatic system. The lymphatic system comprises organs such as the thymus, bone marrow, spleen, and the lymph nodes (or lymph glands). Lymph nodes are connected by a network of tubes called lymphatic vessels that contain lymph fluid and lymphatic tissue is also found in other organs such as skin, lungs and stomach. Prevalence of lymphoblastic lymphoma is high in teenagers and children compared to adults. According to National Cancer Institute (NCI), lymphoblastic lymphoma is the third most common childhood malignancy, and lymphoblastic lymphoma accounts for approximately 7% of cancers in children younger than 20 years. In the United States, in 2013 about 800 new cases of lymphoblastic lymphoma are diagnosed each year.
Lymphoblastic lymphoma is an aggressive lymphoma. This means that it is fast-growing and needs treatment straight away with chemotherapy. The primary symptoms observed in lymphoblastic lymphoma are enlarged lymph nodes, enlarged spleen, thrombocytopenia, fatigue, dyspnea and others. The types of lymphoblastic lymphoma are overactive bladder syndrome, chlamydia, cervical cancer, polycystic ovary syndrome (PCOS), pelvic inflammatory diseases and others.
The lymphoblastic lymphoma is diagnosed by removing enlarged lymph nodes and examining with blood tests, x-rays and scans, lumbar puncture and bone marrow. The first line of treatment for lymphoblastic lymphoma consists of chemotherapy, radiotherapy, stem cell support and steroid therapy. Chemotherapy is the main treatment for lymphoblastic lymphoma usually treated more intensively than other types of lymphomas. The patients are primarily referred to a specialist centre for treatment and it is similar to the treatment for acute lymphoblastic leukaemia. The three types of chemotherapies are used against lymphoblastic lymphoma market such as induction chemotherapy, consolidation therapy and continuing therapy. The potential complications of lymphoblastic lymphoma include opportunistic infections, neutropenic fever (admit the patient), bleeding, and tumor lysis syndrome.
North America was observed to be the largest market for lymphoblastic lymphoma treatment and the major reasons behind this is the increasing prevalence of genetic diseases and advanced diagnostic facilities. In the U.S., the incidence of lymphoblastic lymphoma is roughly 3000-3500 or approximately 1 in 50,000 in 2012. While currently it has peak the incident rate of 2–5 years old, decreasing in incidence with increasing age before increasing again at around 50 years old. Lymphoblastic lymphoma is slightly more common in males than females and an increased incidence in people with a family history of autoimmune diseases, particularly autoimmune thyroid diseases (namely Graves' disease or Hashimoto's thyroiditis). Asia-Pacific were observed to be the most potential market as the developing healthcare facilities and acceptance of modern technology are enhancing the diagnostics of disease where the detection of lymphoblastic lymphoma is easily observed. The high investments were observed in the point of care sector of healthcare in the emerging markets such as India, China, Brazil, Mexico and others that are driving the market growth in these regions.
Some of the key players in this market are Novartis AG, Pfizer Inc., Sanofi SA, Jazz Pharmaceuticals plc, Bristol-Myers Squibb Company, AstraZeneca PLC, Eisai Inc., Amgen Inc. and BioCryst Pharmaceuticals, Inc. Key players involved in the research and development are National Cancer Institute, Fred Hutchinson Cancer Research Center, The University of Texas M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center , St. Jude Children's Research Hospital, Inc., Johann Wolfgang Goethe University Hospitals and others.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY — 12207
United States
Tel: +1-518-618-1030
USA — Canada Toll Free 866-552-3453

Browse Market Research Blogs: